Combination of nonmyeloablative stem cell transplantation and Imatinib in accelerated phase CML.
Baron
Frédéric
F
Department of Medicine, Division of Hematology, University of Liège, Belgium.
Frère
Pascale
P
Herens
Christian
C
Fillet
Georges
G
Beguin
Yves
Y
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001549:Benzamides; D003131:Combined Modality Therapy; D020732:Cytogenetic Analysis; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*; D012074:Remission Induction / Q000379:methods; D033581:Stem Cell Transplantation / Q000379:methods*; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D014916:Whole-Body Irradiation
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D014740:Vidarabine; C024352:fludarabine